Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.
about
Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathiesMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprineRituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Juvenile dermatomyositis: new insights and new treatment strategies.Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study.Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisComparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Juvenile dermatomyositis in a Nigerian girl.Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.Serological subsets of juvenile idiopathic inflammatory myopathies--an update.Treatment of Juvenile Dermatomyositis: An Update.Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.Pharmacological management of dermatomyositis.Cardiac findings in children with juvenile Dermatomyositis at disease presentation.213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.The family impact of caring for a child with juvenile dermatomyositis.Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis.Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.Impact of aging on the clinical features and treatment of polymyositis in adults.Current Classification and Management of Inflammatory Myopathies.
P2860
Q26863125-D63412AC-11ED-4D13-B31B-5D4304F86D70Q27021322-9A4014D6-16C1-4B7F-B73D-E563EB66EBD2Q33717793-3BDEEC33-121D-45E8-99CC-3A9B14B37B62Q34070882-CEBCDADD-542A-4407-BACA-2B2C5CC418BCQ34635470-0439DEF1-FDA9-4EA3-B36A-25CC0D791D19Q34644962-D89BDE9A-D168-4E7D-ABE9-D1E9DE04D174Q35009335-B05077E5-B70E-49B7-8AE6-3CA0A6A9D082Q36059542-D8552858-3B6C-4F79-988F-C182C260C42CQ36498667-70A7B552-8476-408A-88CD-58BE16A1B340Q36619819-6FF3E80A-EFA6-496E-B12D-FB38AA112ECBQ36903076-E03B36E3-E8D0-4859-BF15-C315A34A42B2Q37293030-9F83002C-D34A-4AF8-AA30-F05ED09A0F77Q37316551-2F7D6DB5-F60C-4714-8391-306BC8FA42A6Q37368405-A166B2B3-F8F2-41EC-B1BC-096348DAEBC0Q37427265-1FB27F3F-0982-4B52-98F8-CE83248927FEQ37703673-3C4B8749-8AEA-45D9-A6F5-31475554C929Q37704799-8039BD0B-EE54-4158-BF7B-9EB72A67A1FFQ37938701-84A8AACA-50D5-4A7C-B8DE-22B3768E8A33Q38281749-7EB2599E-C06A-4074-ACA4-B934093EE6CFQ38664251-793E55B6-DB67-4F6B-9519-F37C413D3833Q38678257-B12D5D87-E666-4AD8-9B05-EE5E19996E86Q38786091-FE088CF9-9683-47A2-8512-6C4AD8CE4148Q38836830-DC316A24-47CD-4995-838B-1946C009830DQ39425296-7B045A13-104D-4B59-96E8-A9DF58BE3C95Q39426129-57E440DA-3CCE-47BF-8FC6-81FB022700E2Q42365042-B99B9236-A406-499F-86AB-2E9AE6565B36Q42418314-91515E03-753F-40E4-A0A0-73D8F7A99472Q45359402-5ED4CE82-E805-4C22-A672-C3B7E25592B5Q47425244-31B4F2F0-242B-4BDB-A819-8ABA3C0936DBQ47546564-C9ED5FB3-954F-4D95-910F-2B8BEC28B675Q47800428-D23A5257-E168-4285-B315-5CAA46B0C967Q52884348-D1E99023-5A3B-4272-B707-F3365631A553Q53092243-1DFC8D64-E55A-4950-86E4-02801BFB0A6DQ54291296-F0657D82-295F-4865-B5F3-239B98A81702Q54977148-30BECE9E-BB2F-4EB2-820E-A40E40981D52
P2860
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Damage extent and predictors i ...... ith the myositis damage index.
@en
Damage extent and predictors i ...... ith the myositis damage index.
@nl
type
label
Damage extent and predictors i ...... ith the myositis damage index.
@en
Damage extent and predictors i ...... ith the myositis damage index.
@nl
prefLabel
Damage extent and predictors i ...... ith the myositis damage index.
@en
Damage extent and predictors i ...... ith the myositis damage index.
@nl
P2093
P2860
P50
P356
P1476
Damage extent and predictors i ...... ith the myositis damage index.
@en
P2093
Ann M Reed
Barry L Myones
Brian M Feldman
IMACS Group
Imelda Cabalar
Jason B Monroe
Lauren M Pachman
Maria L Villalba
Peter A Lachenbruch
Robert M Rennebohm
P2860
P304
P356
10.1002/ART.24904
P577
2009-11-01T00:00:00Z